Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
AIxCrypto Holdings, Inc. completed a disposition involving Chembio Diagnostics, Inc. for $5.1 million in cash (closed 2023-07-20).
- Action
- disposition
- Counterparty
- Chembio Diagnostics, Inc.
- Consideration
- $5.1 million in cash
- Closing
- 2023-07-20
Exact text from the filing
the consummation of the Transaction, the Subsidiary became a wholly-owned subsidiary of the Buyer. The aggregate net purchase price paid to the Company for the Shares was $5.1 million in cash, based on a base purchase price of $5.8 million, subject to certain post-closing adjustments, upward or downward, as applicable, for: (i) cash held by the Subsidiary as
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
AIxCrypto Holdings, Inc. entered into Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A. valued at $5.1 million in cash, based on a base purchase price of $5.8 million (effective 2023-07-20).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Chembio Diagnostics, Inc. and Biosynex, S.A.
- Value
- $5.1 million in cash, based on a base purchase price of $5.8 million
- Effective
- 2023-07-20
Exact text from the filing
On July 20, 2023, Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a stock purchase agreement (the “Purchase Agreement”) with Chembio Diagnostics, Inc. (the “Buyer”), Biosynex, S.A. (“Biosynex”), and Qualigen, Inc., a wholly-owned subsidiary of the Company (the “Subsidiary”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
AIxCrypto Holdings, Inc. amended Nanosynex Amendment with Nanosynex Ltd. valued at aggregate amount of $1,610,000 (effective 2023-07-20).
- Action
- amendment
- Agreement
- settlement
- Counterparty
- Nanosynex Ltd.
- Value
- aggregate amount of $1,610,000
- Effective
- 2023-07-20
Exact text from the filing
On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with Nanosynex Ltd. (the “Nanosynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of Nanosynex Ltd. (“Nanosynex”), dated May 26, 2022, by and between the Company and Nanosynex (the “Original Nanosynex Agreement”), a majority owned subsidiary of the Company, to, among other things, provide for the further funding of Nanosynex, as contemplated by the Original Nanosynex Agreement.
View on SEC.gov